Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
iTeos Therapeutics SA (NASDAQ: ITOS) is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. The company is dedicated to transforming the treatment of cancer by designing and developing therapies that aim to activate and restore the immune system's ability to recognize and fight cancer. Their pipeline includes novel drug candidates targeting key immune checkpoints and pathways, such as EOS-448 (anti-TIGIT antibody) and EOS-984 (adenosine A2A receptor antagonist).
The Cambridge headquarters serves as the global operational and strategic hub, overseeing corporate strategy, business development, clinical operations management for US and global trials, investor relations, and general administration.
Situated in the vibrant Kendall Square/East Cambridge biotech ecosystem, providing proximity to leading research institutions, collaborators, and a rich talent pool. The office is likely modern and designed to facilitate collaboration.
The work culture is characterized by a strong focus on scientific innovation, collaboration, and a patient-centric approach. As a clinical-stage biotech, it's likely fast-paced and results-driven, with a commitment to advancing cancer therapies.
The US headquarters is critical for iTeos's engagement with the North American financial markets, regulatory bodies (FDA), clinical trial sites, and the broader US biotech community. Its location underscores the company's global ambitions and its focus on cutting-edge science.
iTeos Therapeutics operates with a significant global footprint, anchored by its global headquarters in Cambridge, MA, USA, and its research and discovery center in Louvain-la-Neuve, Belgium. The company manages global clinical trials across North America, Europe, and potentially other regions, collaborates with international research institutions, and engages in global business development activities to advance its immuno-oncology pipeline worldwide.
955 Massachusetts Avenue, Suite 201
Cambridge
MA
USA
Address: Rue des Waides 8, 1348 Louvain-la-Neuve, Belgium
Acts as the hub for European research and development activities, leveraging the strong scientific environment in Belgium and Europe. It's foundational to the company's origins and ongoing discovery efforts.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, iTeos Therapeutics' leadership includes:
iTeos Therapeutics has been backed by several prominent investors over the years, including:
Over the past 12 months (mid-2023 to mid-2024), iTeos Therapeutics strengthened its leadership by appointing a new Chief Business Officer. No major executive departures were publicly announced during this period.
Discover the tools iTeos Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
iTeos Therapeutics SA primarily utilizes a common corporate email format. The most frequently observed pattern is the first initial of the employee's first name followed by their full last name, all preceding '@iteostherapeutics.com'.
[first_initial][last]@iteostherapeutics.com
Format
jdoe@iteostherapeutics.com
Example
80%
Success rate
GlobeNewswire (via Yahoo Finance) • May 9, 2024
iTeos announced its financial results for the first quarter of 2024, highlighting progress in its clinical programs for EOS-448 (belrestotug) and EOS-984, and outlined upcoming milestones....more
GlobeNewswire • April 8, 2024
The company presented updated positive data from its Phase 1/2 trial of belrestotug in combination with pembrolizumab in patients with advanced solid tumors, demonstrating promising anti-tumor activity and a manageable safety profile....more
GlobeNewswire (via Yahoo Finance) • February 28, 2024
iTeos reported its financial results for Q4 and full year 2023, detailed advancements across its immuno-oncology pipeline, and discussed strategic priorities for 2024....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including iTeos Therapeutics, are just a search away.